After 4 years of follow-up, pembrolizumab demonstrated durable antitumor activity and improved outcomes over ipilimumab in advanced melanoma.
The addition of abemaciclib to fulvestrant significantly improved PFS and time to subsequent chemotherapy in pre- and perimenopausal HR-positive/HER2-negative breast cancer patients.
Extended follow-up from the CheckMate 238 trial confirmed the superior efficacy of nivolumab vs ipilimumab in patients with stage III and IV resected melanoma.
Several different driver mutations acquired during treatment for breast cancer can help explain acquired resistance to the combination of palbociclib and fulvestrant.
The combination of ribociclib and fulvestrant yielded an improvement in progression-free survival in postmenopausal women with advanced breast cancer, according to the MONALEESA-3 trial.
Ribociclib plus endocrine therapy resulted in improved PFS in premenopausal women with HR+, HER2− advanced breast cancer.
Deeper inhibition of the MAPK pathway by targeting both MEK and BRAF may help improve progression-free survival outcomes in patients with advanced BRAF V600–mutated melanoma.
A secondary cytoreductive surgery along with chemotherapy following recurrence in patients with epithelial ovarian cancer offered improved outcomes over treatment with chemotherapy alone.
The presence and burden of single nucleotide variants as measured in cell-free DNA may have substantial prognostic utility in patients with melanoma who have metastases.
Researchers have developed a “disease screening pill” that could allow for a noninvasive and safe method for detecting breast cancer using only near-infrared light.